Cargando…
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining th...
Autores principales: | Ahn, Ryuhjin, Ursini-Siegel, Josie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961781/ https://www.ncbi.nlm.nih.gov/pubmed/33807608 http://dx.doi.org/10.3390/ijms22052608 |
Ejemplares similares
-
Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?
por: Ursini-Siegel, Josie
Publicado: (2013) -
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021) -
Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023) -
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022) -
Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)